CD8A and melanoma: Accordingly, treatment with a-CTLA4-TGFβRII also resulted in higher tumor-reactive IFN-γ-expressing CD8+ cells compared to treatment with a-CTLA-4 in mice bearing human melanoma PDX (Fig. 4g).